MRI-guided radiotherapy for prostate cancer: Lessons from the MIRAGE trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Cancer Institute defines precision medicine in cancer as a strategy that “uses specific information about a person’s tumor to help make a diagnosis, plan treatment, find out how well treatment is working, or make a prognosis.” 

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Amar U. Kishan, MD
Associate professor, Chief of Genitourinary Oncology Service, Vice chair of clinical and translational research, Department of Radiation Oncology, University of California, Los Angeles
Table of Contents

YOU MAY BE INTERESTED IN

Amar U. Kishan, MD
Associate professor, Chief of Genitourinary Oncology Service, Vice chair of clinical and translational research, Department of Radiation Oncology, University of California, Los Angeles

Login